Autor(es): Silva, Sónia ; Sequeira, Telma ; Barata, Fernando
Data: 2024
Origem: THORAC (Thoracic Cancer Journal)
Autor(es): Silva, Sónia ; Sequeira, Telma ; Barata, Fernando
Data: 2024
Origem: THORAC (Thoracic Cancer Journal)
The era of precision medicine has resulted in the identification of several genomic alterations that can be targeted with novel therapies. In lung adenocarcinomas, a histology that accounts for nearly 50% of all cases of lung cancer, a few genomic targets have been linked with effective targeted therapies. For patients with advanced-stage lung adenocarcinomas, molecular testing is now a standard part of diagnostic workup; for patients that have specific driver molecular events, targeted therapies have resulted in substantial improvement in efficacy without excessive toxicity.